Welcome to our dedicated page for Cosmos Health news (Ticker: COSM), a resource for investors and traders seeking the latest updates and insights on Cosmos Health stock.
Cosmos Health Inc. reports developments across a vertically integrated healthcare platform that includes wholesale pharmaceutical distribution, contract manufacturing, proprietary nutraceutical brands and research and development. Recurring updates cover U.S. commercialization of the 18 Series nutraceutical portfolio, including Noor18, Liv18, Cur18 and Fort18, as well as Sky Premium Life orders, international distribution relationships and product launches.
Company news also covers financial results, margin and revenue drivers at Cana Laboratories, CosmoFarm and Decahedron, AI investments including the Cloudscreen drug-repurposing platform, and Nasdaq listing-compliance or governance matters tied to its common stock.
Cosmos Health (NASDAQ:COSM) reported preliminary record Q2 2026 revenue of about $19.4 million, up roughly 31.5% year-over-year from $14.75 million. H1 2026 revenue is expected at about $37.3 million, up roughly 31% from $28.46 million, both all‑time highs.
The company is also executing a share repurchase program of up to $5 million, having bought 3,640,000 shares for about $700,000 in open‑market transactions as of July 6, 2026, with purchases ongoing through December 31, 2026.
Cosmos Health (NASDAQ:COSM) expanded its share repurchase activity, buying an additional 220,000 shares in the open market at an average price of about $0.2229 per share.
Total buybacks under the program have reached 3,640,000 shares, costing approximately $700,000, within an authorization of up to $5 million, effective through December 31, 2026.
Cosmos Health (NASDAQ:COSM) expanded its share repurchase program, buying an additional 770,000 shares at an average price of about $0.1956 per share. Total buybacks now reach 3.42 million shares for roughly $650,000 under a previously authorized up to $5 million program.
The repurchase plan, which follows SEC Rules 10b5-1 and 10b-18, runs through December 31, 2026, with Cosmos Health intending to continue open market purchases subject to market conditions.
Cosmos Health (NASDAQ:COSM) reported completing an initial repurchase of 2,650,000 common shares for $500,000, at an average price of about $0.1887 per share. These open market purchases are part of a share repurchase program of up to $5 million announced on June 30, 2026.
The company plans to continue open market buybacks, subject to market conditions, under a program that runs through December 31, 2026 and may be renewed. Management indicates it views the stock as undervalued and sees repurchases as aligned with its long-term growth and shareholder value strategy.
Cosmos Health (NASDAQ:COSM) authorized a share repurchase program of up to $5 million of common stock. Repurchases may occur in the open market, via private transactions, or other permitted methods under SEC Rules 10b5-1 and 10b-18.
The program, which expires on December 31, 2026, represents almost half of Cosmos Health's market capitalization as of June 29, 2026. Management cites record revenue, improving margins, and global expansion as reasons, and believes the buyback can enhance shareholder value.
Cosmos Health (NASDAQ:COSM) signed a distribution agreement with International Medical Company to expand Sky Premium Life nutraceuticals in Qatar. IMC placed an initial purchase order of 31,000 units. Kulud Pharmacies, IMC's retail arm, is Qatar's largest pharmacy chain, providing nationwide reach.
Cosmos Health (NASDAQ:COSM) reported that subsidiary Cana Laboratories has advanced international patent application WO2025108566A1, covering its CCX0722 hydrogel weight management platform, into the U.S., Europe, Australia, and Canada.
The company now owns the CCX0722 intellectual property outright and targets major markets within a global weight management sector projected to reach $562.2 billion by 2033.
Cosmos Health (NASDAQ:COSM) reported accelerating traction for its proprietary antiseptic C-Sept PRO in leading Greek public and private hospital groups. Average sales exceeded $93,000 per month over six months, rising above $108,000 per month recently, putting annualized sales above $1.3 million at roughly 72% gross margin.
According to Cosmos Health, this creates a high-margin, recurring hospital revenue stream in Greece, with plans to expand the hospital-focused antiseptics business into additional European markets over time.
Cosmos Health (NASDAQ:COSM) signed an agreement to deploy an AI-powered call center for its subsidiary CosmoFarm, supporting order intake and routine customer communications. The multilingual platform will automate inbound and outbound calls, integrate with back-end systems, and provide real-time reporting, targeting process optimization, cost efficiencies, and improved customer experience.
This move extends Cosmos Health’s broader AI strategy, launched in April 2026, which applies AI across front-end and back-end operations. According to Cosmos Health, AI-driven optimization may reduce certain operating expenses by up to 30%, depending on the process and automation level.
Cosmos Health (NASDAQ:COSM) reported that subsidiary Cana Laboratories has built a contract manufacturing orderbook of over 25 million units across multiple EU and international partners and nine therapeutic categories. Multi-year agreements extend up to 10 years, produced at Cana’s upgraded, 54,000 sq. ft. EU-GMP, EMA-certified Athens facility.
Cosmos Health has invested about $5.5 million in facility upgrades, including a new ACG capsule-filling line. At full capacity, the contract manufacturing division is positioned to generate over $10 million in recurring annual profit, with current contracts using only part of available capacity.